his.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Bioengineered T cells for Leukaemia and Lymphoma
Högskolan i Skövde, Institutionen för vård och natur.
2011 (Engelska)Självständigt arbete på avancerad nivå (magisterexamen), 20 poäng / 30 hpStudentuppsats (Examensarbete)
Abstract [en]

Cancer immunotherapy is a promising tool for treatment of malignancies. However, there are still hindrances that need to be overcome. Chimeric antigen receptors have the ability to direct immune cytotoxic cells towards tumour-associated antigens in major histocompatibility complex-independent manner. In this study 2 generations of such receptor-bearing T cells, against the CD19 B-cell marker, were investigated for treatment of chronic lymphocytic leukaemia. The 2 nd generation   of this genetically engineered T cell contains CD3ζ  and CD28 intracellular domain, while the third generation has CD137 (4-1BB) in addition. Previous studies have demonstrated advantages of 2 nd  generation chimeric antigen receptor T cells  compared with 1 st generation. In this project the 2 nd and 3 rd generation T   cells  were compared for transduction efficiency, phenotype, proliferative capacity and cytotoxicity in response to antigen from a malignant B cell line. The analysis of transduction showed similar transduction efficiency for both types of chimeric  antigen receptor. However, the data from T cell phenotyping and cytotoxic analysis could not be used for drawing any conclusion, because of too little amount of samples and subsequently, lack of statistical analysis. Further, the proliferative capacity was similar between all transduced T-cell groups and did not give any   conclusive data. The next step will be to stimulate the 2 nd and 3 rd generation T cells with autologous target cells and follow them for a longer time since  allogeneic tumour cell lines trigger an alloreactivity that may mask the different activation states that may occur in the two T cell products.

Ort, förlag, år, upplaga, sidor
2011. , s. 21
Nationell ämneskategori
Immunologi
Identifikatorer
URN: urn:nbn:se:his:diva-5593OAI: oai:DiVA.org:his-5593DiVA, id: diva2:507756
Ämne / kurs
Molekylärbiologi
Utbildningsprogram
Molekylärbiologi - magisterprogram
Uppsök
medicin
Handledare
Examinatorer
Tillgänglig från: 2012-03-07 Skapad: 2012-03-06 Senast uppdaterad: 2012-03-07Bibliografiskt granskad

Open Access i DiVA

Master thesis report(3173 kB)593 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 3173 kBChecksumma SHA-512
0de000279257e98675b2b2497caeed6be611d790c0d1d68cf7cc55596e316caa8c53110812eadf6c6b67bc42dce1b1465d548a3b117f5c2ce4e9f8a640db53c0
Typ fulltextMimetyp application/pdf

Av organisationen
Institutionen för vård och natur
Immunologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 593 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

urn-nbn

Altmetricpoäng

urn-nbn
Totalt: 269 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf